Menu
Not yet recruiting NCT07268248

1-hour Premedication for Allergy Goal in Emergency: PAGE-1 Study

No phase Interventional Allergic Reaction to Contrast Media Hypersensitivity Reaction Computed Tomography Premedication

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: IV glucocorticoid and antihistamine, IV glucocorticoid and antihistamine (standard of care).
Who it may be relevant to
Registry conditions: Allergic Reaction to Contrast Media, Hypersensitivity Reaction, Computed Tomography, Premedication. Basic parameters: from 21 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

1-hour Premedication for Allergy Goal in Emergency Computed Tomography, A Randomized Controlled Non-inferiority Trial: PAGE-1 Study

Overview

1-hour Premedication for Allergy Goal in Emergency: PAGE-1 is a prospective, parallel, two-arm, non-inferiority, randomized controlled trial evaluating the safety of a 1-hour (intervention) versus a 4-hour (standard regimen) intravenous (IV) premedication protocol in adult patients in the Emergency Department (ED) with a documented iodinated contrast allergy and requiring computed tomography (CT) imaging for a high-risk indication.

Detailed description

Allergic or hypersensitivity reactions to iodinated contrast media are rare, estimated to occur in 0.3% to 1.4% of cases, but have decreased significantly after the switch from high-osmolar to low-osmolar contrast. Most reactions are mild, and breakthrough reactions occur regardless of the timing of premedication. IV premedication is recommended, but there is no level I evidence for its basis in the ED.

This study addresses the sparse evidence that underpins the ubiquitous multi-hour premedication protocols in EDs nationwide. It specifically challenges the existing paradigm of 4-5 hours of IV premedication, which has remarkably never been prospectively validated.

Interventions

  • Other IV glucocorticoid and antihistamine
    Methylprednisolone sodium succinate (e.g., Solu-Medrol®) 40 mg IV immediately plus diphenhydramine 25 mg IV 1 hour before contrast medium administration for CT imaging
  • Other IV glucocorticoid and antihistamine (standard of care)
    Methylprednisolone sodium succinate (e.g., Solu-Medrol®) 40 mg IV immediately 4 hours before contrast medium administration, plus diphenhydramine 25 mg IV 1 hour before contrast for CT imaging

Primary outcome measures

  • Difference in proportion of Acute Contrast Reaction [Time frame: 30 minutes]
  • Proportion of patients eligible for intervention [Time frame: Before randomization]
Secondary outcome measures (2)
  • Proportion randomized to intervention and control [Time frame: Within 30 minutes after completion of CT imaging]
  • Adverse events after intervention [Time frame: Within 30 minutes after assessment of primary outcome]

Eligibility criteria

Inclusion criteria

  • Adult (≥ 21 years old)
  • Documented iodinated contrast allergy in the electronic health record
  • CT with iodinated contrast ordered for a high-risk indication, † defined as post-arrest, concern for aortic dissection, ischemia, occlusion, obstruction, or other life-threatening conditions requiring timely diagnosis
  • Willing and able to give consent

Exclusion criteria

  • Previous enrollment in this study
  • Pregnancy
  • Seafood or iodine allergy, alone
  • Gadolinium allergy

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Prevention

Study locations

Center list to be confirmed — check the primary protocol.

Publications

  • Davenport MS, Cohan RH. The Evidence for and Against Corticosteroid Prophylaxis in At-Risk Patients. Radiol Clin North Am. 2017 Mar;55(2):413-421. doi: 10.1016/j.rcl.2016.10.012. PMID 28126223
  • Greenberger PA, Halwig JM, Patterson R, Wallemark CB. Emergency administration of radiocontrast media in high-risk patients. J Allergy Clin Immunol. 1986 Apr;77(4):630-4. doi: 10.1016/0091-6749(86)90357-x. PMID 3958391
  • Lasser EC, Berry CC, Talner LB, Santini LC, Lang EK, Gerber FH, Stolberg HO. Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material. N Engl J Med. 1987 Oct 1;317(14):845-9. doi: 10.1056/NEJM198710013171401. PMID 3627208
  • Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology. 1990 Jun;175(3):621-8. doi: 10.1148/radiology.175.3.2343107. PMID 2343107
  • Amiri E. Optimizing Premedication Strategies for Iodinated Contrast Media in CT scans: A Literature Review. J Med Imaging Radiat Sci. 2025 Jan;56(1):101782. doi: 10.1016/j.jmir.2024.101782. Epub 2024 Nov 20. PMID 39571411
  • Freed KS, Leder RA, Alexander C, DeLong DM, Kliewer MA. Breakthrough adverse reactions to low-osmolar contrast media after steroid premedication. AJR Am J Roentgenol. 2001 Jun;176(6):1389-92. doi: 10.2214/ajr.176.6.1761389. PMID 11373198
  • Mervak BM, Davenport MS, Ellis JH, Cohan RH. Rates of Breakthrough Reactions in Inpatients at High Risk Receiving Premedication Before Contrast-Enhanced CT. AJR Am J Roentgenol. 2015 Jul;205(1):77-84. doi: 10.2214/AJR.14.13810. PMID 26102383
  • Mervak BM, Cohan RH, Ellis JH, Khalatbari S, Davenport MS. Intravenous Corticosteroid Premedication Administered 5 Hours before CT Compared with a Traditional 13-Hour Oral Regimen. Radiology. 2017 Nov;285(2):425-433. doi: 10.1148/radiol.2017170107. Epub 2017 Jul 26. PMID 28745940

Identifiers

NCT: NCT07268248 · Pro2025002416

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗